Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DexCom, Inc.
FDA Clears Abbott’s Modified CGM For Automated Insulin Delivery Integration, Label Expansion
Abbott announced today it plans to integrate its FDA-cleared modified CGMs with insulin pump makers, including Tandem and Insulet, likely later this year.
News We’re Watching – Medicare Covers Dexcom CGM; New Mpox EUA; $106M Patent Verdict Against Medtronic
Medicare announced coverage for the Dexcom G7 continuous glucose monitor, as well as a breast cancer indication for Natera Inc.’s Signatera; the FDA authorized a new monkeypox test; the FDA issued a warning letter to a Texas masks firm; and a new report says NIST labs are failing behind.
Dexcom Doubles Down On Jonas Branding To Hail G7 Launch
Dexcom is commemorating the US launch of its G7 continuous glucose monitor with an expensive ad spot during the Super Bowl.
Dexcom Touts G7 As ‘The Most Accurate CGM’ As It Prepares For US Launch
The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
- Other Names / Subsidiaries
- SweetSpot Diabetes Care
- TypeZero Technologies, LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.